key: cord-0750886-s57fymbj authors: RUIZ, S.; CONCORDET, D.; LANOT, T.; GEORGES, B.; GOUDY, P.; BAKLOUTI, S.; MANE, C.; LOSHA, E.; VINOUR, H.; ROUSSET, D.; LAVIT, M.; MINVILLE, V.; CONIL, J-M; GANDIA, P. title: Hydroxychloroquine lung pharmacokinetics in critically ill patients infected with COVID-19 date: 2020-11-28 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.106247 sha: 9e5b91ca591589616559c9abe489dcad65a7571d doc_id: 750886 cord_uid: s57fymbj Different dosage regimens of hydroxychloroquine were used to manage COVID-19 patients, with no information on the lungs’ exposure in this population. The aim of our study was to evaluate hydroxychloroquine concentrations in the lung epithelial lining fluid (ELF) in patients infected with COVID-19. This study is a retrospective, observational, multicenter, pharmacokinetics study of hydroxychloroquine in critically ill patients. No additional interventions or additional samples compared to standard care of these patients were conducted in our teaching hospital. We included all intubated COVID-19 patients treated with crushed hydroxychloroquine tablets, regardless of the dosage administered by the nasogastric tube. Blood and bronchoalveolar lavage (BAL) samples (n= 28) were collected from 22 COVID-19 patients and the total hydroxychloroquine concentrations in epithelial lining fluid were estimated. Median hydroxychloroquine plasma concentrations were of 0.09 [0.06; 0.14] mg/l and 0.07 [0.05; 0.08] mg/l for 400 mg x 1/day and 200 mg x 3/day, respectively. Median hydroxychloroquine ELF concentrations were of 3.74 [1.10; 7.26] mg/l and 1.81 [1.20; 7.25] for 400 mg x 1/day and 200 mg x 3/day, respectively. The median ratio of ELF/plasma concentrations was of 40.0 [7.3; 162.7] and 21.2 [18.4; 109.5] for 400 mg x 1/day and 200 mg x 3/day, respectively. Exposure in the ELF is likely to be underestimated due to the concentrations of plasma hydroxychloroquine. In clinical practice, low plasma concentrations should not induce an increase in drug dosage because the lung exposure may already be high. Based on the in vitro work carried out against SARS-CoV-2 and preliminary clinical data, hydroxychloroquine is currently being used in the management of COVID-19 patients [1, 2] . Hydroxychloroquine may have an antiviral action through three main mechanisms: (1) viral entry prevention, (2) impairment of viral replication and (3) pleiotropic action on the human immune system through immuno-modulating activity [3] . The various in vitro studies have shown that the EC 50 of hydroxychloroquine ranged from 0.72 to 4.4 µM (i.e. 0.241 to 1.4 mg/l) at 48 hours and 72 hours post-infection, respectively [3] [4] [5] . Pending the results of robust clinical trials and due to the lack of pharmacokinetic-pharmacodynamic information in COVID-19 patients, and in accordance with the National French Team, AC43-ANRS/STP-SFPT, different dosage regimens were applied in Toulouse University Hospital (France) (200 mg x 3 / day; 400 mg x 2 on day 1 then 200 mg x 3 / day; 400 mg x 2 on day 1 then 400 mg / day; and at least for ICU patients, 600 mg x 2 on day 1 then 400 mg/day) in order to reach pharmacokinetic equilibrium as quickly as possible [6] . Regardless of the dosage regimen, plasma concentration was monitored in order to evaluate individual drug exposure. It has been proven that the plasma concentrations measured in COVID-19 patients tended to be lower than the values reported in SLE patients, in particular for the standard regimen of "200 mg x 3/day" [7] . These preliminary results suggest that hydroxychloroquine concentrations are unlikely to be adequately predicted using the pharmacokinetic models derived from patients receiving hydroxychloroquine for SLE or rheumatoid arthritis treatment [8] . 5 As the apparent volume of distribution of hydroxychloroquine is so large in volunteers as well as in malaria patients (≈ 5 000 l for the blood volume of distribution and ≈ 40 000 l for the plasma volume, at steady state) [9, 10] , it can be suggested that the hydroxychloroquine gets trapped in the red cells and granulocytes [9, 11, 12] and probably in various tissues [10] . It could be assumed that the same occurs for COVID-19 patients. Consequently, it is natural to question the concentration of hydroxychloroquine at the infectious site (i.e. the lung) [13] . Unfortunately, this information is not available. A lung biopsy is the most informative approach. Even if a biopsy is a mixture of both intra-and extra-cellular matrices usually homogenised so as to determine a mean concentration [14] , hydroxychloroquine gets trapped in the cells suggesting this drug is more likely present in the cells rather than outside. However, this option would be highly intrusive and an alternative approach would be to evaluate the hydroxychloroquine concentration in lung epithelial lining fluid (ELF) at the bedside of intensive care unit (ICU) patients [15, 16] . Drug concentration in ELF can be inferred based on the concentration of hydroxychloroquine in the bronchoalveolar lavage (BAL) fluid and the concentration of urea both in the plasma and the BAL fluid [17] . This method is not new and is usually applied to explore the lung diffusion of antibiotics in ICU patients. Consequently, when available, BAL fluid can be used as a kind of "quality control" used to obtain information on the degree of impregnation in the lung for a short period (10-15 days) of treatment. The aim of our study was to evaluate hydroxychloroquine in the lung's ELF in COVID-19 patients in order to estimate the level of lung exposure. 6 This study is a retrospective, observational, multicentre, pharmacokinetic study of hydroxychloroquine in critically ill patients. We included all intubated COVID-19 patients treated with crushed hydroxychloroquine tablets, regardless of the dosage administered by nasogastric tube. According to the guidelines established by the French National AC43-ANRS/STP-SFPT Team in March/April 2020, blood samples were collected at different time points (from 48h to 192h) during clinical management of COVID-19 patients after hydroxychloroquine initiation and 30 minutes before drug administration (i.e. trough concentration). In plasma, the steady state is supposed to be reached in 48 hours [18] . As part of our standard practice for monitoring patients with acute respiratory distress syndrome (ARDS) who are at high risk for infectious complications, and in this particular context of COVID-19, a mini-bronchoalveolar lavage (BAL) (twice 20 ml of physiological saline) was systematically performed 7 days (+/-2 days) after treatment initiation or in the event of a new respiratory degradation, for microbiological monitoring purposes (bacteriology, mycology and viral replication of SARS-CoV-2). A leftover volume of approximately 500 µl remained after these microbiological investigations, which was used to determine the hydroxychloroquine concentration. BAL sampling was carried out between two dose administrations, with no specific time imposed. Except for one case, only the BALs for which plasma determinations were performed within 48 hours before or after collection were included. Hydroxychloroquine in plasma and BAL fluid concentrations were determined using a chromatographic analytical method, validated as per FDA guidelines. All BAL sample 7 preparations included a protein precipitation and a virus inactivation step in a methanol solution. The HCQ dosage method presents a lower limit of quantitation (LLOQ) of 0.05 mg/l in the plasma and 0.01 mg/l in the BAL fluid, an upper limit of quantitation (ULOQ) of 2 mg/l in the plasma and the BAL fluid, and an intra-and inter-day variability of <4% and <10% respectively. When plasma concentrations were